Adjuvant immunotherapy in superficial bladder cancer.
The use of BCG as an intracavitary form of immunotherapy in human bladder cancers is discussed. The result of a clinical trial in which BCG is administered in the treatment of human bladder cancers is reported. Possible uses of this tumor model in the study of immunotherapy employing BCG are suggested.
D000328:Adult; D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*; D014555:Urination Disorders / Q000209:etiology
D001500:BCG Vaccine